Here's what we know about remdesivir, the experimental drug seen as a possible treatment for Covid-19
Vials of investigational coronavirus disease treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US. March 18, 2020.
Much analysis and more studies are needed to understand which Covid-19 patients are most likely to benefit from the drug if it is deemed effective, under what circumstance it should be given, and whether it has any impact on the death rate.The US National Institute of Allergy and Infectious Diseases released preliminary results from a large randomised trial suggesting hospitalised patients with Covid-19 and lung complications recovered 31 percent faster with remdesivir than with a placebo.
Comparing the drug to a placebo should give researchers definitive answers about remdesivir's effect on the illness. After two weeks, more than half the patients in both groups had been discharged from the hospital, and 64.5 percent in the five-day treatment group and 53.8 percent in the ten-day treatment group had recovered.
Lab technicians fill vials of investigational coronavirus disease treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, US. March 18, 2020. In a randomised study of adults hospitalised for severe Covid-19 in Wuhan, China –– the original epicentre of the pandemic –– the 158 patients who received remdesivir did not improve any faster than the 79 patients in a control group who received a placebo.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Gilead Sciences says there are 'positive data' from a study on possible Covid-19 treatment remdesivirThere's 'positive data' emerging from a study on possible Covid-19 treatment remdesivir, the maker of the investigational drug says
Consulte Mais informação »
Study Shows Shorter Course of Gilead Drug as Effective Against Covid-19Gilead Sciences said its phase 3 study for the antiviral remdesivir demonstrated that patients with severe Covid-19 taking the drug over a five-day treatment had similar improvement compared with those taking the 10-day course.
Consulte Mais informação »
Gilead says remdesivir shows improvement in COVID-19 patients when used earlyGilead Sciences Inc on Wednesday said its experimental antiviral drug remdesivir helped improve outcomes for patients with COVID-19, and provided data suggesting it worked better when given earlier in the course of infection.
Consulte Mais informação »
Gilead says early results of coronavirus drug trial show improvement with shorter remdesivir treatmentGilead says preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a 5-day dosage of remdesivir improved, and more than half were discharged from the hospital within 2 weeks.
Consulte Mais informação »
Stocks Rally, Dow Up 400 Points After Gilead Treatment Shows ‘Positive Data’The market got a boost from news of a potential treatment for coronavirus.
Consulte Mais informação »